Trials / Completed
CompletedNCT04471870
ARCANGELO (itAlian pRospective Study on CANGrELOr)
Multicentre Observational, Prospective Cohort Study Including Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Who Receive Cangrelor i.v. Transitioning to Clopidogrel, Prasugrel or Ticagrelor Per os
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,005 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the real clinical practice, evaluating the safety of the transition to all the oral P2Y12 inhibitors (cangrelor, ticagrelor and prasugrel).
Conditions
Timeline
- Start date
- 2020-10-23
- Primary completion
- 2022-01-17
- Completion
- 2022-01-17
- First posted
- 2020-07-15
- Last updated
- 2026-02-20
Locations
30 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04471870. Inclusion in this directory is not an endorsement.